GlassScriptPhysician profile
Jennifer Ann Everson
NPI 1396893780
$5,747.44
in general payments reported to CMS, 2019-2025
55 companies · $1,004 in 2025
The $1,004 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $510 · 2021: $1,215 · 2022: $1,020 · 2023: $584 · 2024: $824 · 2025: $1,004.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,386 · Entertainment: $25.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,385.71 |
| Entertainment | $25.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $702.34 | 2019-2025 | |
| Biogen, INC. | $651.07 | 2024-2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $449.88 | 2021-2025 | |
| Daiichi Sankyo INC. | $361.38 | 2019-2022 | |
| Pfizer INC. | $258.53 | 2022-2025 | |
| Exeltis, USA INC. | $256.61 | 2019-2025 | Slynd |
| Sumitomo Pharma America, INC. | $232.40 | 2023-2025 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $220.95 | 2019-2023 | |
| Millicent US INC | $217.52 | 2020-2025 | Femring, Intrarosa, Femlyv |
| Astellas Pharma US INC | $159.91 | 2020-2025 | Veozah |
| Organon LLC | $156.92 | 2022-2025 | Nexplanon |
| Therapeuticsmd, INC. | $140.49 | 2019-2021 | |
| Myovant Sciences INC. | $139.40 | 2021-2022 | |
| Avion Pharmaceuticals | $132.90 | 2019-2023 | Balcoltra |
| Scynexis, INC. | $102.93 | 2022 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $91.02 | 2023-2024 | Channel Drain, Arista Ah Flexitip |
| Lupin INC. | $87.33 | 2019-2021 | |
| Ethicon US, LLC | $86.83 | 2021-2024 | Evarrest, Surgiflo Hemostatic Matrix, Dermabond Prineo |
| Agile Therapeutics, INC. | $75.62 | 2022-2024 | Twirla |
| Evofem Biosciences, INC. | $75.60 | 2021-2024 | |
| Aspira Women'S Health INC | $74.63 | 2019-2024 | Ova1 |
| Exact Sciences Corporation | $69.08 | 2024-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $67.52 | 2024-2025 | Dexcom G6 Transmitter |
| Amag Pharmaceuticals, INC. | $59.14 | 2019 | |
| Innovation Technologies INC | $58.27 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $56.80 | 2020-2023 | Exparel |
| Coloplast Corp | $55.71 | 2020-2021 | |
| Shield Therapeutics INC | $53.19 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $46.58 | 2019-2021 | |
| Optumhealth Care Solutions, LLC | $40.67 | 2024-2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Smith+Nephew, INC. | $40.14 | 2019-2024 | Pico 7 |
| Boston Scientific Corporation | $39.72 | 2021 | |
| Allergan, INC. | $38.99 | 2019-2020 | |
| Avanos Medical | $37.66 | 2021 | |
| Coopersurgical, INC. | $36.58 | 2021 | |
| Mylan Pharmaceuticals INC. | $29.47 | 2020-2021 | |
| Abbott Laboratories | $28.23 | 2020 | |
| Vertical Pharmaceuticals, LLC | $26.80 | 2019 | |
| Argentum Medical | $25.68 | 2024-2025 | |
| Hologic Sales and Service, LLC | $25.09 | 2024 | Aptima |
| Medtronic, INC. | $24.18 | 2023 | Venaseal |
| Baudax Bio INC. | $22.58 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $19.85 | 2025 | |
| Bausch Health US, LLC | $19.22 | 2025 | Aplenzin |
| Meditrina | $17.46 | 2022 | |
| Renovia INC | $17.32 | 2019 | |
| Heron Therapeutics, INC. | $17.29 | 2023 | Zynrelef |
| Eisai INC. | $17.20 | 2021 | |
| Ascend Therapeutics US, LLC | $16.13 | 2022 | |
| Duchesnay USA Incorporated | $14.87 | 2019 | |
| Mission Pharmacal Company | $14.31 | 2021 | |
| Minerva Surgical, INC | $12.90 | 2022 | |
| Channel Medsystems, INC. | $12.43 | 2022 | |
| Biom'Up France Sas | $12.12 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Everson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.